Maryland biotechnology firms Profectus BioSciences Inc. and Emergent BioSolutions Inc. will receive up to $36 million to develop and manufacture a new vaccine against a type of virus that causes hemorrhagic fever.
{iframe}https://www.bizjournals.com/baltimore/news/2018/08/16/two-marylandbiotechs-get-36-million-to-aid-in-new.html?ana=e_ae_set2&s=article_du&ed=2018-08-16&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1534768436&j=83313021{/iframe}